Transgene and islet cell delivery systems using nano-sized carriers for the treatment of diabetes mellitus

K, Ito; Ookawara, Susumu; Ishibashi, Keiichiro; Morishita, Yoshiyuki

doi:10.1080/20022727.2017.1341758

Cited by 3 publications

(1 citation statement)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a nonspecific inflammatory and thrombotic reaction (instant blood‐mediated inflammatory reaction, IBMIR) may occur when islet cells are exposed to the recipient blood, causing substantial destruction of transplanted islet cells. [ 195 ] However, encapsulating cells in an immunoisolating membrane can enhance their transplantation without the need for immunosuppression. So far, a large number of studies related to islet transplantation have focused on the encapsulation strategies.…”

Section: Nanomaterials For Diabetes Prevention and Therapymentioning

confidence: 99%

Emerging Theranostic Nanomaterials in Diabetes and Its Complications

Liu

Zeng

et al. 2021

Advanced Science

View full text Add to dashboard Cite

Diabetes mellitus (DM) refers to a group of metabolic disorders that are characterized by hyperglycemia. Oral subcutaneously administered antidiabetic drugs such as insulin, glipalamide, and metformin can temporarily balance blood sugar levels, however, long‐term administration of these therapies is associated with undesirable side effects on the kidney and liver. In addition, due to overproduction of reactive oxygen species and hyperglycemia‐induced macrovascular system damage, diabetics have an increased risk of complications. Fortunately, recent advances in nanomaterials have provided new opportunities for diabetes therapy and diagnosis. This review provides a panoramic overview of the current nanomaterials for the detection of diabetic biomarkers and diabetes treatment. Apart from diabetic sensing mechanisms and antidiabetic activities, the applications of these bioengineered nanoparticles for preventing several diabetic complications are elucidated. This review provides an overall perspective in this field, including current challenges and future trends, which may be helpful in informing the development of novel nanomaterials with new functions and properties for diabetes diagnosis and therapy.

show abstract

Section: Nanomaterials For Diabetes Prevention and Therapymentioning

confidence: 99%

Emerging Theranostic Nanomaterials in Diabetes and Its Complications

Liu

Zeng

et al. 2021

Advanced Science

View full text Add to dashboard Cite

show abstract

Chitosan for biomedical applications, promising antidiabetic drug delivery system, and new diabetes mellitus treatment based on stem cell

Othman

Alturki

Abu-Taweel

et al. 2021

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

RNA aptamers specific for transmembrane p24 trafficking protein 6 and Clusterin for the targeted delivery of imaging reagents and RNA therapeutics to human β cells

et al. 2022

View full text Add to dashboard Cite

The ability to detect and target β cells in vivo can substantially refine how diabetes is studied and treated. However, the lack of specific probes still hampers a precise characterization of human β cell mass and the delivery of therapeutics in clinical settings. Here, we report the identification of two RNA aptamers that specifically and selectively recognize mouse and human β cells. The putative targets of the two aptamers are transmembrane p24 trafficking protein 6 (TMED6) and clusterin (CLUS). When given systemically in immune deficient mice, these aptamers recognize the human islet graft producing a fluorescent signal proportional to the number of human islets transplanted. These aptamers cross-react with endogenous mouse β cells and allow monitoring the rejection of mouse islet allografts. Finally, once conjugated to saRNA specific for X-linked inhibitor of apoptosis (XIAP), they can efficiently transfect non-dissociated human islets, prevent early graft loss, and improve the efficacy of human islet transplantation in immunodeficient in mice.

show abstract

Transgene and islet cell delivery systems using nano-sized carriers for the treatment of diabetes mellitus

Cited by 3 publications

References 97 publications

Emerging Theranostic Nanomaterials in Diabetes and Its Complications

Emerging Theranostic Nanomaterials in Diabetes and Its Complications

Chitosan for biomedical applications, promising antidiabetic drug delivery system, and new diabetes mellitus treatment based on stem cell

RNA aptamers specific for transmembrane p24 trafficking protein 6 and Clusterin for the targeted delivery of imaging reagents and RNA therapeutics to human β cells

Contact Info

Product

Resources

About